Literature DB >> 23816404

Properdin in complement activation and tissue injury.

Allison M Lesher1, Bo Nilsson, Wen-Chao Song.   

Abstract

The plasma protein properdin is the only known positive regulator of complement activation. Although regarded as an initiator of the alternative pathway of complement activation at the time of its discovery more than a half century ago, the role and mechanism of action of properdin in the complement cascade has undergone significant conceptual evolution since then. Despite the long history of research on properdin, however, new insight and unexpected findings on the role of properdin in complement activation, pathogen infection and host tissue injury are still being revealed by ongoing investigations. In this article, we provide a brief review on recent studies that shed new light on properdin biology, focusing on the following three topics: (1) its role as a pattern recognition molecule to direct and trigger complement activation, (2) its context-dependent requirement in complement activation on foreign and host cell surfaces, and (3) its involvement in alternative pathway complement-mediated immune disorders and considerations of properdin as a potential therapeutic target in human diseases.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alternative pathway; C3 glomerulopathy; Complement therapeutics; Properdin

Mesh:

Substances:

Year:  2013        PMID: 23816404      PMCID: PMC3730815          DOI: 10.1016/j.molimm.2013.06.002

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  75 in total

Review 1.  Control of the complement system.

Authors:  M K Liszewski; T C Farries; D M Lublin; I A Rooney; J P Atkinson
Journal:  Adv Immunol       Date:  1996       Impact factor: 3.543

2.  A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III.

Authors:  C W Clardy; J Forristal; C F Strife; C D West
Journal:  Clin Immunol Immunopathol       Date:  1989-03

3.  Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.

Authors:  T C Farries; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-05-15       Impact factor: 3.857

4.  Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.

Authors:  T E Mollnes; Y C Ng; D K Peters; T Lea; J Tschopp; M Harboe
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

5.  Resolution and analysis of 'native' and 'activated' properdin.

Authors:  T C Farries; J T Finch; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

6.  Analysis of the natural polymeric forms of human properdin and their functions in complement activation.

Authors:  M K Pangburn
Journal:  J Immunol       Date:  1989-01-01       Impact factor: 5.422

7.  Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III.

Authors:  W S Varade; J Forristal; C D West
Journal:  Am J Kidney Dis       Date:  1990-09       Impact factor: 8.860

8.  Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils.

Authors:  U Wirthmueller; B Dewald; M Thelen; M K Schäfer; C Stover; K Whaley; J North; P Eggleton; K B Reid; W J Schwaeble
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

9.  Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.

Authors:  Y Tanuma; H Ohi; M Hatano
Journal:  Clin Immunol Immunopathol       Date:  1990-08

Review 10.  Properdin: approaching four decades of research.

Authors:  K K Maves; J M Weiler
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

View more
  32 in total

1.  Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.

Authors:  Yoshiyasu Ueda; Takashi Miwa; Damodar Gullipalli; Sayaka Sato; Daisuke Ito; Hangsoo Kim; Matthew Palmer; Wen-Chao Song
Journal:  J Am Soc Nephrol       Date:  2018-06-01       Impact factor: 10.121

2.  Response to Letter to the Editor to Gut microbiota, dietary intakes and intestinal permeability reflected by serum zonulin in women.

Authors:  Sabrina Mörkl; Andreas Meinitzer; Thomas Bernd Dschietzig; Harald Mangge; Sonja Lackner; Sandra Johanna Holasek
Journal:  Eur J Nutr       Date:  2018-12       Impact factor: 5.614

Review 3.  Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation.

Authors:  Dorin-Bogdan Borza
Journal:  Matrix Biol       Date:  2016-09-06       Impact factor: 11.583

4.  Complement Factor H-Related 5-Hybrid Proteins Anchor Properdin and Activate Complement at Self-Surfaces.

Authors:  Qian Chen; Melanie Manzke; Andrea Hartmann; Maike Büttner; Kerstin Amann; Diana Pauly; Michael Wiesener; Christine Skerka; Peter F Zipfel
Journal:  J Am Soc Nephrol       Date:  2015-10-02       Impact factor: 10.121

5.  C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.

Authors:  Allison Lesher Williams; Damodar Gullipalli; Yoshiyasu Ueda; Sayaka Sato; Lin Zhou; Takashi Miwa; Kenneth S Tung; Wen-Chao Song
Journal:  Kidney Int       Date:  2017-01-27       Impact factor: 10.612

Review 6.  Therapeutic control of complement activation at the level of the central component C3.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2015-06-10       Impact factor: 3.144

7.  The effect of long-term systemic immunosuppressive drug use on druse formation: a new perspective to age-related macular degeneration

Authors:  Özkan Sever; Ridvan Mercan
Journal:  Turk J Med Sci       Date:  2020-12-17       Impact factor: 0.973

8.  Fibrinogen-specific antibody induces abdominal aortic aneurysm in mice through complement lectin pathway activation.

Authors:  Hui-fang Zhou; Huimin Yan; Paula Bertram; Ying Hu; Luke E Springer; Robert W Thompson; John A Curci; Dennis E Hourcade; Christine T N Pham
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

9.  Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis.

Authors:  Damodar Gullipalli; Fengkui Zhang; Sayaka Sato; Yoshiyasu Ueda; Yuko Kimura; Madhu Golla; Takashi Miwa; Jianxiang Wang; Wen-Chao Song
Journal:  J Immunol       Date:  2018-06-13       Impact factor: 5.422

Review 10.  Complement in disease: a defence system turning offensive.

Authors:  Daniel Ricklin; Edimara S Reis; John D Lambris
Journal:  Nat Rev Nephrol       Date:  2016-05-23       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.